Bio-Thera Solutions has entered into a partnership with Astra Industrial Group subsidiary, Tabuk Pharmaceutical Manufacturing Company, to bring BAT2206, Jansen's Stelara (ustekinumab) biosimilar, to the Saudi Arabian market.
The Department of Health of the Hong Kong Special Administrative Region, China, has accepted the new drug application (NDA) for oral VELSIPITY (etrasimod) submitted by Everest Medicines, for treating adults with moderately to severely active ulcerative colitis (UC).
Johnson & Johnson has filed a supplemental biologics license application (sBLA) with the US Food and Drug Administration (FDA) seeking approval for TREMFYA (guselkumab)to treat moderately to severely active ulcerative colitis (UC).
GENESIS Pharma has entered into an exclusive distribution agreement with Deciphera Pharmaceuticals for the marketing of Ripretinib in 14 European Union (EU) markets in Central and Eastern Europe.
Alfasigma has entered into an agreement to take over the Jyseleca (filgotinib) business of Galapagos.
Biopharmaceutical company Palisade Bio has received a milestone payment from the US Crohn's and Colitis Foundation for the development of its lead programme, PALI-2108.
Biopharmaceutical company Everest Medicines has received approval from China’s National Medical Products Administration (NMPA) for its new drug application (NDA) related to Xerava (eravacycline) to treat complicated intra-abdominal infections (cIAI) in adults.
Statera Biopharma has announced its intent to enter into a non-binding term sheet with regard to a strategic partnership with Lay Sciences, a development and commercialisation company of innovative solutions to license global manufacturing rights to some of Lay Sciences’ IgY products featuring avian antibodies as an active ingredient.
Zealand Pharma has announced a financing agreement with Oberland Capital Management that includes an upfront payment of $100m in exchange for a seven-year, interest-only secured note.
AbbVie has sought approval from the European Medicines Agency (EMA) for risankizumab (Skyrizi, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), to treat patients who are 16 years and above suffering with moderate to severe active Crohn's disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.